Nature Communications

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

2025-05-17

Full text

DOI https://doi.org/10.1038/s41467-025-59865-1